Want to see CTNM full AI Analyst Report?
Contineum Therapeutics, Inc. Class A (CTNM) Ratios
Contineum Therapeutics, Inc. Class A Ratios
CTNM's free cash flow for Q2 2026 was $-11.51M. For the 2026 fiscal year, CTNM's free cash flow was decreased by $-6.00K and operating cash flow was $-11.50M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 27.50 | 20.69 | 23.29 | 6.41 | 18.99 |
| Quick Ratio | 27.50 | 20.69 | 23.29 | 6.41 | 18.99 |
| Cash Ratio | 7.76 | 2.20 | 2.83 | 0.74 | 1.26 |
| Solvency Ratio | -3.81 | -2.84 | 0.12 | -2.10 | -3.21 |
| Operating Cash Flow Ratio | -5.68 | -3.29 | 3.53 | -2.67 | -7.15 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -5.10 | -21.01 |
| Net Current Asset Value | $ 252.26M | $ 191.61M | $ -70.62M | $ 37.03M | $ 60.85M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.03 | 1.48 | 0.12 | 0.07 |
| Debt-to-Equity Ratio | 0.03 | 0.03 | -2.84 | 0.15 | 0.08 |
| Debt-to-Capital Ratio | 0.03 | 0.03 | 1.54 | 0.13 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 1.54 | 0.00 | 0.06 |
| Financial Leverage Ratio | 1.06 | 1.07 | -1.92 | 1.29 | 1.14 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 111.17 | -5.43 | -17.91 |
| Interest Coverage Ratio | 0.00 | 0.00 | -77.29 | -58.56 | -86.29 |
| Debt to Market Cap | 0.00 | 0.00 | 0.49 | 0.01 | 0.01 |
| Interest Debt Per Share | 0.30 | 0.24 | 7.65 | 0.25 | 0.21 |
| Net Debt to EBITDA | 0.99 | 0.37 | 7.54 | -0.01 | -0.01 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 46.76% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 47.15% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | -32.15% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 46.34% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 45.44% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 45.44% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 98.06% | 100.00% | 100.00% |
| EBT Per EBIT | 88.13% | 83.03% | -144.12% | 106.75% | 101.24% |
| Return on Assets (ROA) | -21.68% | -19.85% | 17.43% | -47.90% | -41.13% |
| Return on Equity (ROE) | -22.98% | -21.34% | -33.44% | -61.76% | -47.09% |
| Return on Capital Employed (ROCE) | -25.50% | -25.09% | -12.87% | -52.73% | -42.86% |
| Return on Invested Capital (ROIC) | -25.28% | -24.91% | -12.57% | -47.19% | -42.07% |
| Return on Tangible Assets | -21.68% | -19.85% | 17.43% | -47.90% | -41.13% |
| Earnings Yield | -18.94% | -11.16% | 5.84% | -6.27% | -7.49% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.14 | 0.00 | 0.77 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 35.79 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.38 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.61 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -2562.07 | 0.00 | -477.05 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 2562.07 | 0.00 | 477.05 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.00 | -1.27 | 0.77 | -0.80 | -1.05 |
| Free Cash Flow Per Share | -2.01 | -1.29 | 0.75 | -0.81 | -1.05 |
| Dividend Paid and CapEx Coverage Ratio | -239.45 | -63.90 | 46.74 | -170.52 | -156.35 |
| Capital Expenditure Coverage Ratio | -239.45 | -63.90 | 46.74 | -170.52 | -156.35 |
| Operating Cash Flow Coverage Ratio | -6.70 | -5.25 | 0.10 | -3.44 | -5.35 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.39 | 0.00 | 0.00 |
| Free Cash Flow Yield | -17.54% | -8.81% | 4.86% | -5.23% | -6.83% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.27 | -8.96 | 17.13 | -15.96 | -13.34 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 7.79 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.21 | 1.91 | -5.73 | 9.86 | 6.28 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.70 | -11.35 | 20.56 | -19.12 | -14.64 |
| Price-to-Operating Cash Flow Ratio | -5.72 | -11.53 | 20.12 | -19.23 | -14.73 |
| Price-to-Earnings Growth (PEG) Ratio | -0.16 | 0.01 | -0.09 | 1.02 | 0.00 |
| Enterprise Value Multiple | -3.68 | -8.64 | 24.05 | -16.46 | -13.67 |
| Enterprise Value | 249.27M | 363.09M | 566.96M | 387.29M | 387.29M |
| EV to EBITDA | -3.68 | -8.64 | 24.05 | -16.46 | -13.67 |
| EV to Sales | 0.00 | 0.00 | 11.34 | 0.00 | 0.00 |
| EV to Free Cash Flow | -4.49 | -10.88 | 29.94 | -19.14 | -14.65 |
| EV to Operating Cash Flow | -4.51 | -11.05 | 29.30 | -19.25 | -14.75 |
| Tangible Book Value Per Share | 9.42 | 7.66 | -2.69 | 1.56 | 2.45 |
| Shareholders’ Equity Per Share | 9.42 | 7.66 | -2.69 | 1.56 | 2.45 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 1.98 | 0.00 | 0.00 |
| Net Income Per Share | -2.17 | -1.63 | 0.90 | -0.97 | -1.15 |
| Tax Burden | 1.00 | 1.00 | 0.98 | 1.00 | 1.00 |
| Interest Burden | 0.88 | 1.00 | 0.99 | 1.02 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.55 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.13 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 |
| Income Quality | 0.92 | 0.78 | 0.85 | 0.83 | 0.91 |
Currency in USD
